CD274 and neoplasm: Integrating locoregional therapies such as radiofrequency ablation into anti-PD-1/PD-L1 agent regimens may help release tumor-associated antigens and mediate T-cell immune enhancement and, in the long run, improve the ongoing efficacy of checkpoint inhibitors (39).